About: Full-length title: Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Full-length title: Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Full-length title: Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
Creator	Raoult, Didier Colson, Philippe Rolain, Jean-Marc Gautret, Philippe Brouqui, Philippe Parola, Philippe Lagier, Jean-Christophe Fenollar, Florence Fournier, Pierre-Edouard Million, Matthieu Zandotti, Christine Drancourt, Michel Stein, Andreas Aubry, Camille Doudier, Barbara Esteves-Vieira, Vera Giraud-Gatineau, Audrey Tissot-Dupont, Hervé Amrane, Sophie Eldin, Carole Hocquart, Marie Mailhe, Morgane Scola, Bernard Chabrière, Eric Honoré, Stéphane Roussel, Yanis Berenger, Cyril Cassir, Nadim Correard, Florian Deharo, Jean-Claude Dhiver, Catherine Jacquier, Alexis Levasseur, Anthony Obadia, Yolande Ravaux, Isabelle Seng, Piseth Tomei, Christelle Deharo, Jacquier Hervé, Tissot-Dupont Rolain, Chabrière Scola, La Sté, Honoré
Source	Elsevier; Medline; PMC; WHO
abstract	BACKGROUND: In France, the combination hydroxychloroquine (HCQ) and azithromycin (AZ) is used in the treatment of COVID-19. METHODS: We retrospectively report on 1061 SARS-CoV-2 positive tested patients treated with HCQ (200 mg three times daily for ten days) + AZ (500 mg on day 1 followed by 250 mg daily for the next four days) for at least three days. Outcomes were death, clinical worsening (transfer to ICU, and >10 day hospitalization) and viral shedding persistence (>10 days). RESULTS: A total of 1061 patients were included in this analysis (46.4% male, mean age 43.6 years – range 14–95 years). Good clinical outcome and virological cure were obtained in 973 patients within 10 days (91.7%). Prolonged viral carriage was observed in 47 patients (4.4%) and was associated to a higher viral load at diagnosis (p < .001) but viral culture was negative at day 10. All but one, were PCR-cleared at day 15. A poor clinical outcome (PClinO) was observed for 46 patients (4.3%) and 8 died (0.75%) (74–95 years old). All deaths resulted from respiratory failure and not from cardiac toxicity. Five patients are still hospitalized (98.7% of patients cured so far). PClinO was associated with older age (OR 1.11), severity at admission (OR 10.05) and low HCQ serum concentration. PClinO was independently associated with the use of selective beta-blocking agents and angiotensin II receptor blockers (p < .05). A total of 2.3% of patients reported mild adverse events (gastrointestinal or skin symptoms, headache, insomnia and transient blurred vision). CONCLUSION: Administration of the HCQ+AZ combination before COVID-19 complications occur is safe and associated with very low fatality rate in patients.
has issue date	2020-05-05(xsd:dateTime)
bibo:doi	10.1016/j.tmaid.2020.101738
bibo:pmid	32387409
has license	no-cc
sha1sum (hex)	0388be152d5f261b96211975a404e5d7f9bd0cb4
schema:url	https://doi.org/10.1016/j.tmaid.2020.101738
resource representing a document's title	Full-length title: Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
has PubMed Central identifier	PMC7199729
has PubMed identifier	32387409
schema:publication	Travel Med Infect Dis
resource representing a document's body	covid:0388be152d5f261b96211975a404e5d7f9bd0cb4#body_text
is schema:about of	named entity 'COVID-19' named entity 'azithromycin' named entity 'Journal' named entity 'retrospective' named entity 'Full-length' named entity 'Million' named entity 'AZITHROMYCIN' named entity 'COVID-19' named entity 'COVID-19' named entity 'Treatment' named entity 'France' named entity 'azithromycin' named entity 'Full-length' named entity 'COVID-19' named entity 'hydroxychloroquine' named entity 'United States' named entity 'G6PD deficiency' named entity 'standard deviation' named entity 'hypokalaemia' named entity 'ground glass opacities' named entity 'COVID-19' named entity 'Veterans Health Administration' named entity 'intensive care unit' named entity 'HCQ' named entity 'CT scan' named entity 'electrocardiogram' named entity '8 days' named entity 'respiratory failure' named entity 'NCBI' named entity 'co-infection' named entity 'antivirals' named entity 'computed tomography' named entity 'genomes' named entity 'April 18' named entity 'COVID' named entity 'intensive care unit' named entity 'viral load' named entity 'electrolyte' named entity 'HCQ' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software